The Relationship between the Transforming Growth Factor 𝛽1 T29C Gene Polymorphism and Left Ventricular Geometry and Function in Hypertensive Subjects

Table 2

Distribution of clinical measurements in the hypertensives with left ventricular hypertrophy subgrouped according to Leu¹⁰→Pro¹⁰ TGF𝛽1 genotypes*.

	TT n. 30	TC n. 128	CC n. 40
Gender(F/M)	16/14	60/68	14/26
Age	55 ± 10	50 ± 9	50 ± 9
Weight (Kg)	69 ± 11	72 ± 10	70 ± 9
Height (m)	1.67 ± 0.1	1.65 ± 0.1	1.68 ± 0.1
BMI (Kg/m^2)	24 ± 2	25 ± 2	24 ± 3
WHR	0.85 ± 0.1	0.87 ± 0.1	0.87± 0.1
SBP (mmHg)	143 ± 16	146 ± 16	141 ± 16
DBP (mmHg)	87 ± 10	90 ± 11	89 ± 8
MBP (mmHg)	105 ± 11	108 ± 11	106 ± 9
Antihypertensive drugs
Diuretics	3/30 (10%)	10/128 (7.9%)	4/40 (10%)
ACEi	16/30 (53.4%)	75/128 (58.6%)	19/40 (47.5%)
ARB	12/30 (40%)	58/128 (42.1%)	14/40 (35%)
CaCB	4/30 (13.3%)	12/128 (8.4%)	6/40 (15%)

F: Female; M: Male; BMI: Body mass index; WHR: waist hip ratio; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; MBP: Mean blood pressure; ACEi: angiotensin converting enzyme inhibitors; ARB: Angiotensin receptor blockers; CaCB: calcium channel blockers.
*All variables were not significantly different among the groups.